Shaik Nayeem Uddin: Clopidogrel and Omeprazole Combination Can Quietly Reduce A Life-Saving Effect
Shaik Nayeem Uddin, Global Outreach – Student of the Member American Society for Microbiology, shared a post on LinkedIn:
“A commonly prescribed combination can quietly reduce a life-saving effect.
Let that sink in.
Clopidogrel is a prodrug.
It needs CYP2C19 to become active.
Now introduce Omeprazole.
CYP2C19 gets inhibited, which leads to reduced activation and consequently decreased protection.
What this really means is:
A patient you’re trying to protect from thrombosis may not be getting the full benefit of therapy.
This matters more in:
- Post-MI patients
- Stent placements
- High cardiovascular risk cases
The fix isn’t complicated.
Prefer Pantoprazole when needed
Simple change. Real impact.
Here’s the bigger point:
Drug interactions aren’t rare. They’re routine and often overlooked.
And this is exactly where clinical thinking matters.
This is Part 1 of my series:
Drug Interactions Every Clinician Should Know
If you’re in healthcare, this is something you’ll see more often than you think.
Have you encountered this in clinical practice?”

Stay updated with Hemostasis Today.
-
May 23, 2026, 01:51Paula Greter: Access and Innovation in Hemophilia through ERAH2026
-
May 22, 2026, 17:30Veronica Sanchez: Do You Live with Pain after a Stroke?
-
May 22, 2026, 17:25Maxime Dely: A Simple but Powerful Indicator of Platelet Quality
-
May 22, 2026, 17:24Jim Hoffman: A New Approach to Balancing Host Defense and Tissue Protection
-
May 22, 2026, 17:22Lucia Rugeri: Advancing Multidisciplinary Care for Heavy Menstrual Bleeding in Women with Bleeding Disorders
-
May 22, 2026, 17:20Nour Al-Mozain: Optimizing PBSC Collection Through Real-Time CD34+ Monitoring
-
May 22, 2026, 16:30Buse Bor: New Publication on Therapeutic Interventions for Women with Obstetric APS
-
May 22, 2026, 16:29Danny Hsu: The Reversal Dilemma – Rethinking our approach to DOAC-associated ICH
-
May 22, 2026, 16:28Bartosz Hudzik: High Bleeding Risk Does Not Always Mean Bleeding-Risk Predominance